229 related articles for article (PubMed ID: 17365170)
1. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
2. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
3. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
4. Selegiline transdermal system: a novel treatment option for major depressive disorder.
Nandagopal JJ; DelBello MP
Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
6. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
[TBL] [Abstract][Full Text] [Related]
7. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
8. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
[TBL] [Abstract][Full Text] [Related]
9. The role of monoamine oxidase inhibitors in depression treatment guidelines.
Thase ME
J Clin Psychiatry; 2012; 73 Suppl 1():10-6. PubMed ID: 22951237
[TBL] [Abstract][Full Text] [Related]
10. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
11. A critical appraisal of the selegiline transdermal system for major depressive disorder.
Bied AM; Kim J; Schwartz TL
Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
[TBL] [Abstract][Full Text] [Related]
12. Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Carlat DJ
Psychopharmacol Bull; 2007; 40(3):29-31. PubMed ID: 18007566
[No Abstract] [Full Text] [Related]
13. Monoamine oxidase inhibitors revisited: what you should know.
Goldberg JF; Thase ME
J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
[No Abstract] [Full Text] [Related]
14. The transdermal delivery system of monoamine oxidase inhibitors.
VanDenBerg CM
J Clin Psychiatry; 2012; 73 Suppl 1():25-30. PubMed ID: 22951239
[TBL] [Abstract][Full Text] [Related]
15. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
[TBL] [Abstract][Full Text] [Related]
16. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
Thase ME
J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
[No Abstract] [Full Text] [Related]
17. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
18. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
19. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
Flockhart DA
J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
[TBL] [Abstract][Full Text] [Related]
20. Transdermal selegiline: new opportunity for managing depression.
Tobe EH
J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
